Tag: apellis pharmaceuticals
February 28, 2019
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
Apellis Pharmaceuticals (NASDAQ:APLS) has announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals. As... December 21, 2018
Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA
Apellis Pharmaceuticals (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of... December 20, 2018
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
Apellis Pharmaceuticals (Nasdaq:APLS) today provided an update on the status of its Phase 3 program for APL-2 in patients with Geographic... December 4, 2018
